<List><item><source>MED</source><extId>29774030</extId><pmcid>PMC5944263</pmcid><annotations><annotation><prefix>-Î±2b treatment (ClinicalTrials.gov: </prefix><exact>NCT01729663</exact><postfix>). </postfix><tags><tag><name>NCT01729663</name><uri>http://identifiers.org/clinicaltrials/NCT01729663</uri></tag></tags><id>http://europepmc.org/articles/PMC5944263#europepmc-e9dae077242b6d2ef5abda94d7164da5</id><type>Accession Numbers</type><section>Case study (http://purl.obolibrary.org/obo/IAO_0000613)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> II/III clinical trial (CASVAC-0401, </prefix><exact>NCT01729663</exact><postfix>). </postfix><tags><tag><name>NCT01729663</name><uri>http://identifiers.org/clinicaltrials/NCT01729663</uri></tag></tags><id>http://europepmc.org/abstract/MED/29774030#europepmc-f811e69d8acce6a176047778cb792e01</id><type>Accession Numbers</type><section>Abstract (http://purl.org/dc/terms/abstract)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>